John L. Fahey, B.Sc., Ph.D.
168 Eastwood Drive
Copperhill, Tennessee 37317
Tel: 423-496-5190
Ph.D. Chemistry, Stevens Institute of Technology, New Jersey. Synthesis of Penicillin and Cephalosporin Analogs.
B.Sc. Honours, Chemistry, University of St. Andrews, Scotland, UK.
Available for consultant contracts. Call 423-496-5190 or write to johnfahey2013@gmail.com
Hoffman-La-Roche, New Jersey, 1997, Medical writer of Phase III protocols.
Pfizer International, New York. 1997, Serious Adverse Event Reviewer, Phase III studies.
IBAH (CRO), New Jersey, 1997, Regulatory oversight and approval of Investigator documentation.
Pfizer International, New York. 1998, CRF medical review and management, Phase III studies.
IBAH (CRO), Pennsylvania, 1999, Regulatory oversight and approval of Investigator documentation.
Covance (CRO), New Jersey, 1999, CRF review of Phase III studies..
Clinical Research Associate, Schering-Plough, New Jersey, monitoring sites in the USA for Phase III Hepatitis C studies with interferon/ribavirin.
Dual responsibilities as Director of Clinical Research at the Community Research Initiative and St. Luke's-Roosevelt Hospital, Manhattan, New York, working with Dr. Bernard Bihari and Dr. Joseph Sonnabend, training physicians and nurses conducting Phase II and Phase III AIDS clinical trials, recruitment of patients, writing protocols, negotiating protocols and budgets with Pharmaceutical sponsors, supervising all studies consistent with GCP regulations as required for FDA approval.
1997-1999
1995-1996
1990-1994
1984-1989
Clinical Project Director, Organon, New Jersey, working with Dr. Abraham Feigenbaum, in charge of a deep venous thrombosis program, writing Phase II and Phase III protocols for fractured hip, replacement hip and major abdominal surgery, recruiting investigators, arranging investigator meetings, supervising CRAs, monitoring study sites, writing clinical summary reports, investigator brochures and package inserts.
1978-1983
Professor of Chemistry at Fairleigh Dickinson University, Rutherford, New Jersey, teaching freshman classes to nurses and pre-med students, undergraduate classes in organic chemistry, graduate classes in organic chemistry, molecular biology, interpretive spectroscopy, synthetic methodology in organic chemistry and natural products chemistry. I developed a program for co-operative education that was adopted as a model program by the American Chemical Society and was elected President of the faculty union (AAUP) and President of the Sigma Xi chapter of the ACS.
1977-1978
Faculty Research Scientist at Stevens Institute of Technology under a contract I negotiated with A.H. Robins to develop synthetic methodology for beta-lactams.
I was elected president of the Sigma Xi Chapter of the ACS and initiated a student exchange program with St. Andrews University in Scotland which is now the Stevens Honors program for exceptional students.
1973-1977
Senior Research Scientist, Merck, Sharp & Dohme Research Laboratories, Rahway, New Jersey. As a member of the beta-lactam antibiotic group I synthesised C-3 substituted cephalosporins, then 1-oxa and 1-carba cephalosporins, and during that work I recognised a crude fermentation extract to be a novel beta-lactam by its infrared spectrum. I was assigned to the synthesis team to prove its structure where I achieved the crucial closure to a bicyclic beta-lactam. That compound, known then as thienamycin, is now imipenem, an antibiotic with a wide spectrum profile, that became known as the first carbapenem.
1970-1972.
Ph.D. thesis work at Stevens Institute of Technology.
1968-1970
Research Assistant, Warner-Lambert Research Institute, Morris Plains, New Jersey. I was a member of the clonidine group but then discovered and developed a novel class of compounds that exhibited a wide range of biological activities including anti-hypertensive activity and catechol O-methyl transferase inhibition
1963-1967
Undergraduate chemistry student at the University of St. Andrews, Scotland, UK.
1961-1963
Laboratory Assistant, Billingham ICI, UK. Inorganic analysis and standardisation laboratory.
Professional Honors: Numerous elective and appointive positions, invited speaker for various organizations.
Publications
1.
Preparation of meso, (+)- and Optically Active forms of 3,6-bis(1-hydroxy-1-phenylpropyl) and 3,6-bis(1-hydroxy-phenylethyl)-1,2,4,5-tetrazines via a new synthesis of 1,2-dihydro-1,2,4,5-tetrazines from Amidines.
J.L. Fahey, P.A. Foster, D.G. Neilson, K.M. Watson, J.L. Brokenshire and D.A.V. Peters, J. Chem. Soc., (C), 1970, 719.
2.
1-(2-Imidazolin-2-yl)-2-imidazolines. The structure of Jaffe's Base and the Chemistry of related compounds.
Raymond R. Wittekind, Thomas Capiris, John Fahey, and John Shavel. J. Org. Chem., 38, 1641, (1973).
3.
A 5-methylthiopenicillin Analog and its Transformation to Novel Bicyclic beta-lactams. Ajay K. Bose, J.L. Fahey and M.S. Manhas. J. Het. Chem.,10, 791, (1973).
4.
Studies on Lactams XXIX, Synthesis of Aza Analogs of Cepham. Ajay K. Bose, John L. Fahey and M.S. Manhas. J. Org. Chem., 38, 3437, (1973).
5..
A 5-methylthiopenicillin Analog and its Transformation to a Novel Bicyclic beta-lactam. Ajay K. Bose and John L. Fahey. Fourth International Congress of Heterocyclic Chemistry, July 8-13, 1973.
6.
Studies on Lactams XXX. Synthesis of Dihydropyrroles and Tetrahydropyridines as intermediates for bicyclic beta-lactams. A.K. Bose, J.L. Fahey and M.S. Manhas. Tetrahedron, 30, 3, (1974).
7.
An exocyclic Thio Analog of the Penicillin System. Ajay K. Bose and John L. Fahey.J. Org. Chem., 39, 115, (1974).
8.
C-3 Modified Cephalosporins, John L. Fahey, R.A. Firestone and B.G. Christensen. Meeting in Miniature, Stevens Institute of Technology, May 14, 1975.
9.
3-Cyanocephems and C-3 Heterocyclic Substituted Cephems via 1,3-dipolar Cycloadditions, John L. Fahey, Raymond A. Firestone and B.G. Christensen, J. Med. Chem., 19, 562, (1976).
10.
Novel 3-pyrazole cephalosporin antibiotics and diazoalkane intermediates, U.S. Patent 3,979,384 (9-7-76).
11.
Penicillin and Cephalosporin Analogs with methylthio substitution. John L. Fahey, Barry C. Lange, James M. Van der Veen, George R. Young and Ajay K. Bose, J.C.S. Perkin I, 1117, (1977).
12.
2000-present
Development and ownership of informational web domain ErinPharm. Focus on events occurring on medical/scientific research frontiers that will lead to optimal healthy longevity. Documenting developments in vascular research and understanding of longevity syndromes.
ErinPharm - http://www.erinpharm.org/erinpharm_central.html
Total syntheses of (+/-)-1-carbacefoxitin and -cefamandole and (+/-)-1-oxacefamandole. Firestone RA, Fahey JL, Maciejewicz NS, Patel GS, Christensen BG. J Med Chem. 1977 Apr;20(4):551–556
Twitter: @JohnFahey11
